Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

Psoriasis is a common chronic inflammatory skin condition that affects 3–4% of the adult US population [1]. Surveys have shown that despite the availability of topical, oral, and systemic treatments, a substantial portion of patients with psoriasis remain undertreated relative to the severity of their disease, leading to high dissatisfaction rates [2]. Untreated psoriasis is associated with severe impairment in social, occupational, and overall well-being, with physical and emotional impact that increases with disease severity [2, 3]. Thus, new therapies with enhanced long-term efficacy and safety are needed by dermatologists for the treatment of moderate-to-severe psoriasis.

Ixekizumab is currently one of three biologic agents (along with secukinumab and brodalumab) that target the interleukin (IL)-17 cytokine pathway. IL-17 is a proinflammatory cytokine produced primarily by type 17 helper (TH17) T cells [4]. Specifically, IL-17A, one of the 6 homodimers of IL-17, is considered the most potent isoform in psoriasis development [5, 6] and exerts its effect by binding the IL-17 receptor subunit A (IL-17RA) [7]. Ixekizumab is a humanized monoclonal immunoglobulin G (IgG) 4 antibody that acts by specifically binding to and inhibiting IL-17A, thus inhibiting the inflammatory changes culminating in psoriasis. IL-17 contributes a role in the activation and recruitment of neutrophils, the blockade of neutrophil apoptosis, and the stimulation of psoriasis angiogenesis [6, 8‐10]. Evidence of elevated levels of IL-17 in psoriatic lesions and in the serum of patients with psoriasis further support the role of IL-17 in the pathophysiology of psoriasis [11‐15].

In the following article, we review the results of the pivotal Phase III trials regarding the efficacy and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. The co-primary endpoints examined include at least a 75% reduction in psoriasis area and severity index (PASI 75) and static physician global assessment (sPGA) of 0 (clear) or 1 (almost-clear) on a 5-point scale by week 12 of treatment. sPGA is a tool used by clinicians to document their impression of disease severity, with scores ranging from 0 (clear) to 4 (severe disease). We also examined the long-term efficacy, up to 60 weeks, in the clinical trials that have been completed to date.

We reviewed the published results of the Phase III clinical trials for ixekizumab to determine the percentage of patients with psoriasis who had a positive response to the therapy. To identify all the studies that addressed ixekizumab, we performed an English language literature search from January 2003 to September 2015 using PubMed with any of the following key words: “ixekizumab” and “psoriasis” or “IL-17” and “psoriasis”. We also reviewed citations within articles to identify relevant resources and examined recent dermatologic posters for preliminary data as well. Pooled measures of efficacy and incidence of adverse events for each medication were calculated by tabulating values from independently conducted studies.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Three major Phase III clinical trials, UNCOVER-1, UNCOVER-2, and UNCOVER-3 (ClinicalTrials.gov identifiers: NCT01474512, NCT01597245, and NCT01646177, respectively) were conducted to evaluate efficacy and safety of different dosing frequencies of ixekizumab compared to placebo [16, 17]. UNCOVER-2 and UNCOVER-3 also compared ixekizumab to etanercept. The comparisons in baseline demographics are shown in Table 1, while the results from each of these trials are displayed in Table 2. The differences between the endpoints at week 12 are recorded in Table 3.

The results of Phase III clinical trials reinforce the theory that ixekizumab is an effective agent in the treatment of plaque-type psoriasis. At week 12, the proportion of patients achieving PASI 75 or sPGA scores of 0 or 1 was comparable between each respective dosage among the three trials and far superior to the portion of patients that received placebo (Table 1; Fig. 1). The extended data from UNCOVER-1 suggest that the trend of positive results was maintained through 60 weeks of treatment. In UNCOVER-2 and UNCOVER-3, ixekizumab 80 mg Q2W and 80 mg Q4W were found to perform significantly better than etanercept 50 mg twice weekly, a contemporary biologic agent currently approved by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe plaque psoriasis., The superiority of ixekizumab is most pronounced in terms of the proportion of patients who achieve PASI 90 and PASI 100 (Table 1). This is significant because these efficacy endpoints are more substantial than PASI 75 from a patient perspective, as demonstrated by a study finding that patients who achieve PASI 90 or PASI 100 experience greater improvement in quality of life than PASI 75 responders [18]. The availability of this novel, highly efficacious class of biologic medication offers new hope for patients whose psoriasis remains recalcitrant to the older biologic agents.

Within the context of these Phase III trials of ixekizumab, the most common adverse events included nasopharyngitis, upper respiratory tract infection, injection-site reaction, and headache. Most adverse events were mild or moderate in severity. A small portion of patients (less than 9%) experienced low-grade neutropenia while on ixekizumab 80 mg Q2W or ixekizumab 80 mg Q4W, though the cases were transient and without associated infections. Based on findings in patients with genetic IL-17 immunity deficiencies, anti-IL-17 agents may theoretically increase the risk for mucocutaneous candidiasis infection [19, 20]. In the trials reviewed here, mild and moderate Candida infections were more frequent among patients taking ixekizumab than placebo. However, all Candida infections were mild to moderate in intensity and resolved without discontinuation of treatment.

There are currently three IL-17 pathway inhibitors that have completed Phase III testing: secukinumab, brodalumab, and ixekizumab. There are several differences among these drugs with potential clinical implications. With regards to frequency of injections, ixekizumab provides a more favorable option with only 4 syringes applied by the end of the first month for the 80 mg Q2W regimen, compared to secukinumab that requires 10 syringes applied by the end of the first month for the 300 mg regimen (both dosing regimens are the highest for the respective drug). With regards to brodalumab, the number of syringes involves in the first 4 weeks is similar to ixekizumab in that only four injections of single syringes are needed. However, in the maintenance phase, which can go on for years, brodalumab is unique in that its most efficacious dosage requires every other week injection, as opposed to secukinumab and ixekizumab, both of which only require monthly maintenance injections.

Secukinumab, currently the only agent among the three that is FDA approved, and brodalumab are fully human monoclonal antibodies, whereas ixekizumab is a humanized antibody. This difference may affect immunologic reactivity, as fully human antibodies are theorized to result in a smaller degree of immunogenicity relative to humanized antibodies [21]. Clinically, a higher degree of immunogenicity may result in long-term loss of efficacy secondary to antibody production against the drug [22]. However, studies have found similar immunogenicity among high scoring humanized antibodies, such as ixekizumab, and fully human antibodies [21, 23]. A high scoring humanized antibody is an antibody that contains nonhuman regions, yet still acts almost identically to a fully human antibody in studies. Furthermore, ixekizumab is an IgG4 isotype, a bispecific molecule in vivo that would have the potential for drug reactions. However, ixekizumab has been shown to be functionally monovalent, meaning that it does not have the same potential for drug reactions as other IgG4 isotypes [24]. Finally, ixekizumab and secukinumab are antibodies against IL-17A, whereas brodalumab is an antibody that targets the IL-17 receptor, thus antagonizing all IL-17 subtypes. Thus far, there have been no head-to-head comparisons of these drugs to directly verify efficacy and safety of one agent over the other.

In addition to treating the cutaneous symptoms of psoriasis, ixekizumab as an IL-17 pathway inhibitor may provide additional systemic benefits. Between 5% and 30% of patients with psoriasis suffer from concomitant psoriatic arthritis, a progressive and irreversible condition that merits systemic therapy [25, 26]. Increased levels of IL-17 and IL-17 receptor are present in the synoviocytes and synovial fluid of psoriatic arthritis patients compared to those of patients with osteoarthritis [27, 28]. Accordingly, a Phase III clinical trial demonstrated that ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis at 24 weeks, as measured by the proportion of patients achieving an American College of Rheumatology 20% improvement response (ACR20) [29]. Recent epidemiologic studies also suggest that treating the systemic inflammatory state associated with psoriasis leads to a reduction of cardiovascular events such as myocardial infarction and stroke [30]. On a molecular level, elevated levels of IL-17 have been measured in atherosclerotic plaques [31], which are thought to act in coordination with other proinflammatory cytokines in plaque formation [32]. Moreover, elevated levels of IL-17 are present in patients who suffer from unstable angina and acute myocardial infarction [33]. Taken together, these findings suggest that antagonizing the IL-17 pathway may serve to alleviate the symptoms of psoriatic arthritis and reduce the risk of cardiovascular events in patients with psoriasis [34].

Ixekizumab has yielded promising data in terms of efficacy and safety for the treatment of chronic plaque psoriasis. Ixekizumab 80 mg Q2W and ixekizumab 80 mg Q4W have demonstrated to be more efficacious in terms of PASI 75, PASI 90, and PASI 100 at week 12 as compared with etanercept 50 mg twice weekly or placebo. Further data from open-label extension studies are necessary to confirm the favorable efficacy and safety profile of this agent demonstrated in the Phase III trials.